For the quarter ending 2025-09-30, OTLC had $320,978 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss before non-controlling interests | -1,114,369 | -153,815 |
| Amortization of debt discount and deferred finance costs | 54,478 | 81,095 |
| Loss on debt conversion | - | 0 |
| Stock based compensation | 183,742 | - |
| Change in fair value of derivative | -392,058 | 424,830 |
| Prepaid expenses and other current assets | -20,894 | 1,487 |
| Accounts payable and accrued expenses | 155,661 | 204,904 |
| Accounts payable to related party | 514 | 1,027 |
| Net cash used in operating activities | -307,022 | -293,106 |
| Proceeds from sales of common stock | - | 0 |
| Repaid to note holders | - | 0 |
| Proceeds from convertible debt | 478,000 | 0 |
| Repaid to related party/others | - | 0 |
| Proceeds from / (repayment to) private placement | - | 0 |
| Proceeds from short term loans, others | 150,000 | 295,000 |
| Net cash provided by financing activities | 628,000 | 295,000 |
| Net increase (decrease) in cash | 320,978 | 1,894 |
| Cash and cash equivalents at beginning of period | 106,128 | - |
| Cash and cash equivalents at end of period | 429,000 | - |
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)